John Overdeck’s Creative Medical Technology CELZ Stock Holding History

John Overdeck’s Portfolio CELZ Stock Details CELZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-13,106	Closed	-$40.6K	–	3235
2024 Q3	$40.6K	Sell	13,106 -1,703	-11%	-$5.77K	﹤0.01%	2980
2024 Q2	$57K	Sell	14,809 -89	-0.6%	-$403	﹤0.01%	2877
2024 Q1	$77.6K	Buy	+14,898	New	+$69.3K	﹤0.01%	2853

Other funds holding CELZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

John Overdeck's CELZ Position: Q4 2024 in Review

John Overdeck sold out of Creative Medical Technology (CELZ) in Q4 2024, closing a stake of 13,106 shares — an estimated $40.6K sold.

John Overdeck first reported a position in CELZ in Q1 2024 and held it in 3 quarters. The position peaked at $77.6K in Q1 2024. 8 funds tracked by Wall St. Rank hold CELZ as of Q4 2024.

John Overdeck reported no remaining Creative Medical Technology position as of Q4 2024 after selling out during the quarter.
John Overdeck sold 13,106 Creative Medical Technology shares in Q4 2024, an estimated $40.6K.
John Overdeck first reported a position in Creative Medical Technology in Q1 2024 and held it in 3 quarters.
John Overdeck's Creative Medical Technology position peaked at $77.6K in Q1 2024.
8 funds tracked by Wall St. Rank held Creative Medical Technology as of Q4 2024.

Based on Two Sigma Investments's 13F filing for Q4 2024, filed 14 Feb 2025.